Northwell Holdings and Aegis Ventures company Caire, a virtual care creation platform, has appointed former emeritus president and CEO of Mayo Clinic, Dr. John Noseworthy, as executive chairman.
Noseworthy will join the company's board of directors and lead its Caire Collaborative, a consortium of health systems that act as investors, partners and early adopters of Caire's in-person and virtual...
British multinational pharmaceutical and biotech company GSK announced a three-year agreement with a $70 million initial payment to expand its access to Tempus' AI-powered data library, including its de-identified patient data.
GSK says the collaboration will allow it to leverage the U.S.-based company's library to accelerate drug discovery in oncology, improve its clinical trial design,...
AI-enabled pathology company PathAI has entered into a multiyear drug discovery partnership with pharma giant GlaxoSmithKline.
The agreement will focus on advancing clinical trials and drug development in oncology and for nonalcoholic steatohepatitis (NASH), an aggressive type of fatty liver disease that can lead to serious scarring and liver failure.
"Our partnership will combine GSK and PathAI...
AI-enabled pathology company PathAI is partnering with the Cleveland Clinic to use its algorithms for clinical care and research.
The five-year collaboration will allow the startup and the academic medical center to digitize "hundreds of thousands" of pathology specimens, creating whole slide images across multiple diseases. When combined with molecular data, the partners will have a large...
PathAI, maker of AI-enabled pathology products, announced Friday it was partnering with pharma and diagnostics giant Roche.
The strategic partnership will allow PathAI to develop and distribute its AI pathology tech through Roche’s uPath enterprise software, a workflow platform for labs.
The collaboration will begin with distributing PathAI’s research-use-only algorithms through the cloud...
Boston-based PathAI is adding a suite of laboratory testing services to its portfolio of artificial intelligence-powered pathology tools through its acquisition of Poplar Healthcare Management.
Poplar Healthcare is a Memphis, Tennessee-based laboratory services provider to a nationwide client base of gastroenterologists, dermatologists, oncologists, urologists, gynecologists and their patients....
PathAI, a Boston-based artificial intelligence pathology company, has closed a Series C funding round worth $165 million.
The round was co-led by D1 Capital Partners and Kaiser Permanente, with additional participation from General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, and strategic partners Bristol-...
Boston-based PathAI, maker of artificial intelligence tools for pathology, has capped off its Series B funding round with a $15 million strategic investment from the Merck Global Health Innovation Fund and Bristol-Myers Squibb. This raise brings the startup’s full round to $75 million, and its total funding to just over $90 million.
WHAT THEY DO
PathAI’s platform employs convolutional neural...
Yesterday PathAI, a Boston-based maker of artificial intelligence tools for pathology, closed a $60 million Series B funding round led by General Atlantic. Other existing investors, most notably General Catalyst, also participated in the round.
To monitor its investment, General Atlantic Managing Director Dr. Michelle Dipp will also be joining the AI company’s board of directors.
WHAT THEY DO...
Last month, Novartis announced that it would be cutting 2,200 jobs as part of a restructuring of the company focusing on particular priorities.
“The overall strategy we have is to focus the company as a leading medicines company powered by digital technologies,” CEO Vas Narasimhan told STAT News last month. “What that has meant is to exit certain health care sectors or segments … — so we exited...
